Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
81.36 USD | -1.23% | -4.34% | +13.92% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 138M | Sales 2025 * | 157M | Capitalization | 1.46B |
---|---|---|---|---|---|
Net income 2024 * | 92M | Net income 2025 * | 50M | EV / Sales 2024 * | 10.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.28 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
25.2
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | -1.23% | ||
1 week | -4.34% | ||
Current month | -4.34% | ||
1 month | +11.12% | ||
3 months | +12.27% | ||
6 months | +32.51% | ||
Current year | +13.92% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 26 M€ | -4.59% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 81.36 | -1.23% | 142,479 |
24-06-06 | 82.37 | -1.47% | 96,534 |
24-06-05 | 83.6 | +3.43% | 85,814 |
24-06-04 | 80.83 | -8.05% | 203,347 |
24-06-03 | 87.91 | +3.36% | 128,569 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.92% | 1.46B | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- LGND Stock